Twist Bioscience Corp. Stock News

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon

You can't say Cathie Wood is afraid to make big bets. The investing guru is more than willing to lay it all on the line for stocks she believes in.

While 2023 was the year of the Magnificent Seven, the seven outperforming stocks in this article are likely to be winners that will surge past the broader indices, such as the S&P 500 and the Nasdaq.

Twist Bioscience reported strong results in the first quarter of FY2024, despite a tepid demand environment. Growth was somewhat exaggerated by lumpy NGS revenue, but overall the business is progressi

Twist Bioscience Corporation (TWST) Q1 2024 Earnings Call Transcript

Genomics is undeniably medicine's future, and genomics stocks stand to be the next big thing in healthcare as the industry matures. But the crux of the matter is when the industry will mature.

Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term

ARK Innovation ETF (ARKK), which provides thematic multi-cap exposure to innovation across sectors, has gained 35.2%, becoming the best-performing ETF of November.

Twist Bioscience (TWST) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.94. This compares to loss of $0.91 per share a year ago.

Today, we take a look synthetic biology company Twist Bioscience Corporation for the first time since spring. The company recently signed collaboration deals with two new drugmakers and saw upward ana

Twist continues to expand its SynBio and NGS businesses, but its Biopharma business has had execution issues. Twist is focused on reducing costs, but it is still probably at least several years from G

DNA is as fundamental to biotechnology as it is to biology itself. From synthetic biology to pharmaceuticals, making and using DNA is usually a necessary first step in bringing a biotech product to ma

Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs and EGS Officer Dr. Emily Leproust -

Twist makes synthetic biology and next-generation sequencing tools. The company reported improved revenue and reduced losses in the quarter.

Twist Bioscience (TWST) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $1.08 per share a year ago.